Last updated: July 17, 2026

Application No. 18/485,352

COMPOSITIONS USEFUL FOR TREATING SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA)

Non-Final OA

Filed

Oct 12, 2023

Priority

Apr 12, 2021 — provisional 63/173,885 +6 more

Examiner

HUDSON, AMY ROSE

Art Unit

1636

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The Trustees of the University of Pennsylvania

OA Round

1 (Non-Final)

Interview Optional

— +11.2% interview lift. Interview lift (+11.2%) is below the 15.0% threshold. A written response is recommended.

Based on 1451 resolved cases, 2023–2026

Examiner Intelligence

HUDSON, AMY ROSE View full profile →

Grants 75% — above average

Career Allowance Rate

1089 granted / 1451 resolved

+15.1% vs TC avg

Moderate +11% lift

Without

With

+11.2%

Interview Lift

resolved cases with interview

Typical timeline

2y 5m

Avg Prosecution

70 currently pending

Career history

1509

Total Applications

across all art units

Statute-Specific Performance

§101

1.7%

-38.3% vs TC avg

§103

47.9%

+7.9% vs TC avg

§102

8.3%

-31.7% vs TC avg

§112

20.1%

-19.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1451 resolved cases

Prosecution Timeline

Oct 12, 2023

Application Filed

Mar 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/629,211

Patent 12680102

miRNAS FOR REDUCING VENTRICLE ENLARGEMENT

4y 5m to grant Granted Jul 14, 2026

17/900,919

Patent 12680099

COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES

3y 10m to grant Granted Jul 14, 2026

17/624,125

Patent 12668797

COMPOSITIONS AND METHODS FOR TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA

3y 11m to grant Granted Jun 30, 2026

17/907,323

Patent 12668798

ANTISENSE NUCLEIC ACID TARGETING APOC3

3y 9m to grant Granted Jun 30, 2026

17/910,166

Patent 12668819

CRISPR-AID USING CATALYTICALLY INACTIVE RNA-GUIDED ENDONUCLEASE

3y 9m to grant Granted Jun 30, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

75%

Grant Probability

86%

With Interview (+11.2%)

2y 5m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1451 resolved cases by this examiner. Grant probability derived from career allowance rate.